Dexmedetomidine pharmacokineticpharmacodynamic modelling in healthy volunteers:1. Influence of arousal on bispectral index and sedation by Colin, P. J. et al.
  
 University of Groningen
Dexmedetomidine pharmacokineticpharmacodynamic modelling in healthy volunteers
Colin, P. J.; Hannivoort, L. N.; Eleveld, D. J.; Reyntjens, K. M. E. M.; Absalom, A. R.;
Vereecke, H. E. M.; Struys, M. M. R. F.
Published in:
British Journal of Anaesthesia
DOI:
10.1093/bja/aex085
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Colin, P. J., Hannivoort, L. N., Eleveld, D. J., Reyntjens, K. M. E. M., Absalom, A. R., Vereecke, H. E. M., &
Struys, M. M. R. F. (2017). Dexmedetomidine pharmacokineticpharmacodynamic modelling in healthy
volunteers: 1. Influence of arousal on bispectral index and sedation. British Journal of Anaesthesia, 119(2),
200-210. https://doi.org/10.1093/bja/aex085
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
C L I N I C A L P R A C T I C E
Dexmedetomidine pharmacokinetic–
pharmacodynamic modelling in healthy volunteers: 1.
Influence of arousal on bispectral index and sedation
P. J. Colin1,2,*, L. N. Hannivoort1, D. J. Eleveld1, K. M. E. M. Reyntjens1,
A. R. Absalom1, H. E. M. Vereecke1 and M. M. R. F. Struys1,3
1Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands, 2Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent,
Belgium and 3Department of Anaesthesia and Peri-operative Medicine, Ghent University, Ghent, Belgium
*Corresponding author. E-mail: p.j.colin@umcg.nl
Abstract
Background. Dexmedetomidine, a selective a2-adrenoreceptor agonist, has unique characteristics, such as maintained re-
spiratory drive and production of arousable sedation. We describe development of a pharmacokinetic–pharmacodynamic
model of the sedative properties of dexmedetomidine, taking into account the effect of stimulation on its sedative
properties.
Methods. In a two-period, randomized study in 18 healthy volunteers, dexmedetomidine was delivered in a step-up fashion
by means of target-controlled infusion using the Dyck model. Volunteers were randomized to a session without background
noise and a session with pre-recorded looped operating room background noise. Exploratory pharmacokinetic–
pharmacodynamic modelling and covariate analysis were conducted in NONMEM using bispectral index (BIS) monitoring of
processed EEG.
Results. We found that both stimulation at the time of Modified Observer’s Assessment of Alertness/Sedation (MOAA/S)
scale scoring and the presence or absence of ambient noise had an effect on the sedative properties of dexmedetomidine.
The stimuli associated with MOAA/S scoring increased the BIS of sedated volunteers because of a transient 170% increase in
the effect-site concentration necessary to reach half of the maximal effect. In contrast, volunteers deprived of ambient noise
were more resistant to dexmedetomidine and required, on average, 32% higher effect-site concentrations for the same effect
as subjects who were exposed to background operating room noise.
Conclusions. The new pharmacokinetic–pharmacodynamic models might be used for effect-site rather than plasma con-
centration target-controlled infusion for dexmedetomidine in clinical practice, thereby allowing tighter control over the de-
sired level of sedation.
Clinical trial registration. NCT01879865.
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Clinical Practice
Dexmedetomidine use in clinical practice is popular because of its
unique characteristics as a selective a2-adrenoceptor agonist. It is
currently licensed for sedation in intensive care units in Europe
and the USA and for procedural sedation in the USA. Moreover,
there is frequent off-label use, for instance for procedural sedation
(in Europe), sedation during awake fibreoptic intubation, and
awake craniotomies. Patients under dexmedetomidine sedation
experience little respiratory depression, are more easily roused,
and are better able to communicate compared with propofol or
midazolam sedation.1 Also, dexmedetomidine has been investi-
gated as a possible opioid-reducing technique2 and might attenu-
ate perioperative inflammatory responses.3
For sedation in intensive care units, a slow titration to effect,
with or without a loading dose, is acceptable, because a fast on-
set of effect is often not necessary. However, during procedural
sedation or in the operating room, a faster onset of effect is of-
ten desired. Fast titration to the desired effect with limited or no
overshoot, thereby limiting potential side-effects, can be at-
tained using target-controlled infusion (TCI). For effect-site TCI,
an accurate pharmacokinetic–pharmacodynamic (PKPD) model
is necessary. Currently, only pharmacokinetic (PK) models are
available for dexmedetomidine; no PKPD models.
We recently published an optimized dexmedetomidine PK
model.4 In this twin paper, we describe the pharmacodynamic ef-
fects of dexmedetomidine in healthy volunteers, and model these
effects into PKPD models. In this article, we describe and model the
sedative effects of dexmedetomidine using our previously pub-
lished PK model, and using bispectral index (BIS) and the Modified
Observer’s Assessment of Alertness/Sedation (MOAA/S) as mea-
sures of sedative effects. In an accompanying paper,5 we describe
and model the haemodynamic effects of dexmedetomidine.
Methods
Study design
This study was approved by the local medical ethics review
committee (METC, University Medical Center Groningen,
Groningen, the Netherlands; METC number: 2012/400) and was
registered in the ClinicalTrials.gov database (NCT01879865).
Written informed consent was obtained from all volunteers.
The study conduct was described in detail by Hannivoort and
colleagues,4 who reported on the development of a pharmacoki-
netic model based on measured dexmedetomidine plasma con-
centrations collected throughout the study.
In brief, 18 healthy volunteers, nine male and nine female,
stratified according to age and sex (18–34, 35–54, and 55–72 yr)
received dexmedetomidine i.v. on two separate occasions, at
least 1 week and at most 3 weeks apart. Both sessions were
identical in protocol, except for the use of acoustic noise-
cancelling headphones (Bose QuietComfort 15, Framingham,
MA, USA), either without background noise or with pre-recorded
looped operating room background noise (monitor beeps and
alarms, air conditioning noise, talking, equipment noise etc.). In
both sessions, the volunteers were instructed to keep their eyes
closed throughout the session, and they were stimulated as lit-
tle as possible apart from at set times for the assessment of
depth of sedation. Randomization using sealed envelopes was
used to determine the order of the ‘background silence’ and
‘background noise’ sessions.
Standard anaesthesia monitoring was applied, with the in-
clusion of an arterial line for blood pressure monitoring and
blood sampling, as described by Hannivoort and colleagues.4 An
initial short infusion, given at 6 mg kg1 h1 for 20 s, was
followed by a 10 min recovery period. Thereafter, dexmedetomi-
dine was delivered as a TCI using the Dyck model6 with step-
wise increasing targets of 1, 2, 3, 4, 6, and 8 ng ml1. Each target
was maintained for 30 min. The maximal infusion rate was lim-
ited to 6 lg kg1 h1 for the first four steps; for the target of 6 and
8 ng ml1, the maximal infusion rate was increased to 10 lg kg1
h1 to facilitate attainment of the target within a reasonable
time. Volunteers were monitored until 300 min after cessation
of the TCI dexmedetomidine infusion. The syringe pump
(OrchestraVR Module DPS, OrchestraVR Base A; Fresenius Kabi, Bad
Homburg, Germany) that was used to deliver the dexmedetomi-
dine infusion was controlled by RUGLOOP II software (Demed,
Temse, Belgium) programmed with the Dyck model.6
Pharmacodynamic measurements
A BIS Vista monitor (Covidien, Boulder, CO, USA) was used to re-
cord BIS continuously to study depth of hypnosis. The MOAA/S
scale was used to quantify the level of sedation and rousability of
the volunteer at the following time points: immediately before the
start of dexmedetomidine infusion, 2 min after the start of the ini-
tial short infusion, immediately before the start of the TCI infu-
sion, and at the end of each TCI target step. During the recovery
period, MOAA/S scores were recorded every 2 min for the first
30 min, and every 10 min thereafter, until the volunteer reached
the maximal score on the MOAA/S scale. All monitored parame-
ters were recorded electronically using RUGLOOP II software.
Data handling
The final data set contained BIS measurements at a sampling rate
of 1 Hz, which, for some subjects, resulted in>30 000 observations
per session. To reduce the computational burden, we reduced the
number of BIS measurements per subject. We also applied a me-
dian filter to reduce the influence of artifacts, outlying data, or
both during model development. The width (span) of the median
filter was 60 s. Data reduction was performed by retaining the first
out of every 50 consecutive median filtered observations.
The data set used for modelling contained a median of 372
(range 115–556) BIS measurements per subject per session, cor-
responding to a sampling rate of 1 min1. All unfiltered
MOAA/S observations were retained in the data set, with a me-
dian of 25 (range 8–40) observations per subject per session.
Population pharmacokinetic–pharmacodynamic
modelling
The PKPD modelling was based on individual PK parameter esti-
mates from the dexmedetomidine PK model published
Editor’s key points
• Most target-controlled infusion (TCI) programmes are
based on plasma concentrations rather than effect-site
concentrations.
• Using a previously developed pharmacokinetic model,
effect-site concentrations were modelled from bispectral
index and sedation scale pharmacodynamic data in 18
healthy volunteers.
• The resulting pharmacokinetic–pharmacodynamic
model will be useful in developing improved TCI pro-
grammes that more tightly control sedation using ef-
fect-site concentrations.
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previously.4 The individual predicted PK parameters (V1, V2, V3,
CL, Q2, and Q3) derived from this model were fixed for each indi-
vidual and each session (Hannivoort and colleagues4 reported
that V1 was different between occasions) during further phar-
macodynamic (PD) modelling.
Different structural models were evaluated to test whether
hysteresis exists between the individually predicted dexmede-
tomidine plasma concentrations (IPREDplasma) and PD measures.
Direct models relating IPREDplasma directly to the PD measure
were compared against delay drug effect models, such as an ef-
fect compartment model or an indirect response model. Drug
effects were described using linear, Emax and sigmoid Emax
models.
Once the base model structure was established, graphical
analysis was conducted to identify potential correlations be-
tween post hoc predicted PKPD parameters and subject covari-
ates. Subject covariates considered were as follows: weight,
height, BMI, age, sex, and session (background silence vs back-
ground noise). These covariates were tested in the model, and
the resulting change in goodness of fit (GOF) was evaluated. For
the continuous covariates (age, height, and weight), a linear re-
lationship was assumed, whereas for the categorical covariate
(sex), an additional parameter was added to differentiate be-
tween males and females. Where appropriate, inclusion of
model parameters, covariates, or both was tested at the 5% sig-
nificance level by comparing the decrease in objective function
(OFV) against the critical quantile of the corresponding v2 distri-
bution (e.g. a 3.84 decrease in OFV for inclusion or exclusion of a
single parameter).
Population pharmacodynamic modelling of the
confounding effect of the rousability on BIS
During dexmedetomidine sedation, the stimulation inherent in
MOAA/S scoring results in a transient increase (arousal) in BIS.
The MOAA/S observations were regarded as a sudden, instanta-
neous stimulation of the subject, and the perturbation in BIS
was modelled as a leftward shift in the effect-site concentration
necessary to reach half of the maximal effect (C50). Thus, there
are two BIS curves corresponding to a stimulated (aroused) and
unstimulated (non-aroused) pharmacodynamic state. The dissi-
pation of arousal (equation 1) was modelled using a single pa-
rameter (kin), in conjunction with an indirect response model
(IRM). The pharmacodynamic arousal state is used as a linear
interpolation between two sigmoid drug effect models (given by
equations 2 and 3), as described in equation (4):
dRELAX
dt
¼ kin  1  A RELAXð Þð Þ½  (1)





BISi;STIM ¼ Baseline BISi  1 
Ce
Ce þ ½C50;i  ð1 þ DC50;iÞ
 
(3)
BISi tð Þ ¼ BISi;NSTIM  A RELAXð Þ þ BISi;STIM  1 A RELAXð Þð Þ (4)
In short, an unstimulated subject is in a state of relaxation
(i.e. non-aroused), during which the ‘amount’ in the relaxation
compartment [i.e. A(RELAX)] equals 1. At the moment of stimu-
lation, the compartment is reset, i.e. the ‘amount’ in this com-
partment is set to zero, corresponding to a stimulated, aroused
state. Thereafter, the state returns to a state of relaxation at a
rate of kin. As seen from equation (4), the amount in the
relaxation compartment is used as a linear interpolation be-
tween an unstimulated (equation 2) and a stimulated (equation
3) BIS model. In equations (2) and (3), the dexmedetomidine
effect-site concentration (Ce) to achieve half of the maximal de-
crease in BIS in an unstimulated patient is given by C50, whereas
the proportional change in the C50 for a stimulated subject is de-
scribed by DC50.
Population pharmacodynamic modelling of categorical
MOAA/S observations
Categorical MOAA/S observations were modelled using a model
for ordered categorical variables. This model was parameterized
such that the parameters estimate cumulative probabilities (e.g.
the probability of observing an MOAA/S score3) on the logit
scale. Inter-individual variability (IIV) and drug effect were im-
plemented on these baseline logits using an exponential and
an additive component, respectively. Inclusion of random ef-
fects beyond the IIV on the baseline logits was not considered
to avoid issues with identifiability of the model parameters.
Equation (5) gives an example of the model for the logit of
the cumulative probability (Pr) of observing an MOAA/S
score3.





The baseline logit is described by a typical value for the logit
to be equal to zero (hLLE0), including an exponential random ef-
fect (gi) on this logit and additional terms to estimate the differ-
ence between successive logits (e.g. hD01 estimates the
difference between the logit for an MOAA/S score1 and the
logit of MOAA/S¼0). The drug acts to increase the baseline logit
according to a sigmoid Emax model based on the predicted
effect-site concentration (Ce). The parameters of this sigmoid
Emax model describe the maximal change in the logit (Emax), the
effect-site concentration necessary to reach half of the maximal
effect (C50) and the Hill coefficient of the concentration–effect
relationship (c). The logits were back-transformed to cumulative
probabilities using the inverse of the logit transformation.
Subsequently, the probabilities for each category were obtained
by subtraction from the cumulative probabilities, with the prob-
ability to observe an MOAA/S score 5 being 1.
Parameter estimation and model evaluation
The first-order conditional estimation algorithm with interac-
tion (FOCE-I) as implemented in NONMEMVR (version 7.3; Icon
Development Solutions, Hannover, MD, USA) was used to fit BIS
data. For the categorical MOAA/S data, the Laplacian approxi-
mation to the likelihood was used. Inter-individual variability
and inter-occasion variability (IOV) were modelled using
an exponential model. Residual unexplained variability
was described using additive or proportional error models, or
both.
During model building, the GOF of the different models was
compared numerically using the Akaike information criterion
(AIC) and the median absolute (population-) prediction error
(MdAPE). At each stage, GOF was graphically evaluated by in-
specting plots of the individual or population predicted vs ob-
served responses, and plots of the conditionally weighted
residuals (CWRES) vs individual predictions and time. As a safe-
guard to over-parameterization, only models with a condition
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number of the Fisher information matrix (FIM) <500 were re-
tained in the model building hierarchy. Finally, models were
validated internally using prediction-corrected visual predictive
checks (pcVPC) according to Bergstrand and colleagues.7
All models were fitted to the data using PsN8 and Pirana9 as
back or front end, or both, to NONMEMVR . The numerical and graph-
ical assessment of the GOF and the construction of the pcVPCs
were conducted in RVR (R Foundation for Statistical Computing,
Vienna, Austria). All simulations were performed in a Microsoft
Excel Macro-Enabled Worksheet (Microsoft Office Professional Plus
2013), which is supplied in the Online Supplementary material.
The worksheet depends on the ‘PKPD tools for Excel’ package de-
veloped by T. Schnider and C. Minto, which is available from http://
www.pkpdtools.com/excel (last accessed April 18th 2017).
Statistical analysis
All model parameters are reported as typical values with associ-
ated relative standard errors (RSE) and 95% confidence intervals
(CIs) derived from log-likelihood profiling.10
Results
Data
Figure 1 shows the median filtered BIS signal and the observed
MOAA/S for four representative subjects from our study during
the step-up TCI administration. The dashed lines indicate when
a new TCI target was set. Immediately before changing the TCI
100 5 1 ng ml−1
1 ng ml−1 2 ng ml−1
2 ng ml−1 3 ng ml−1
ID 1 ID 3
NoiseSilence
ID 1 ID 3
NoiseSilence
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Fig 1 Median filtered BIS values and MOAA/S observations for the step-up TCI administration for four representative subjects. Dashed vertical lines indicate
when a new TCI target was set. Immediately before this, MOAA/S was assessed. BIS, bispectral index; MOAA/S, Modified Observer’s Assessment of Alertness/
Sedation; TCI, target-controlled infusion.
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target, MOAA/S was scored. This figure clearly shows the pertur-
bation in the BIS signal induced by stimulating the subjects at
the time of MOAA/S scoring and the subsequent attenuation of
the effect of stimulation. The complete time courses of BIS and
MOAA/S observations for all subjects used for modelling are
shown in Online Supplementary Figs S1 and S2.
Model development for BIS
In a first attempt to describe the effect of dexmedetomidine on
BIS measurements, a sigmoid Emax model was used. Rousability
was accounted for according to equations (1)–(4), and the delay
between plasma PK and BIS effects was described using an ef-
fect compartment model. Modifications to this base structure
were evaluated. Firstly, the Hill coefficient (c) was fixed to 1, re-
sulting in a decrease in the condition number from 1327 to 120;
at the same time, the MdAPE decreased from 13.1 to 13.0%.
Secondly, a logit transform, as shown in equations (6) and (7),
was used to describe the intersubject variability in BIS at base-
line. The inclusion of the logit transformation decreased the
MdAPE further to 12.8%. Under this transformation, all baseline
BIS predictions are restricted between 0 and 100. This signifi-
cantly improved the pcVPC for the BIS model.
Baseline BISi ¼ 100 
e Logitið Þ














The significance of the rousability component of the model
was evaluated by exclusion of this component, as described by
equations (1), (2) and (4), from the final model. The resulting de-
crease in GOF (DAIC¼þ2358) and simultaneous increase in the
MdAPE to 13.5% underpin the importance of accounting for
arousal in the BIS model. Furthermore, a comparison between
the parameter estimates for both models revealed a significant
shift in ke0 (0.120 vs 0.991 min
1), baseline BIS (96.8 vs 89.7), and
C50 (2.63 vs 4.78 ng ml
1) upon removal of the rousability compo-
nent. Inclusion of inter-occasion variability on the estimated
PKPD parameters did not significantly improve the GOF of the
model. Inclusion of age, weight, height, or sex did not result in a
significant decrease in the OFV. Therefore, no covariates were
included in the final model.
Final model for BIS
The final model parameters are described in Table 1. The likeli-
hood profiles, which were generated to identify potential prob-
lems with parameter identification, are shown in Online
Supplementary Fig. S3. Goodness-of-fit plots, such as post hoc
predictions vs observations and CWRES vs time, are shown in
Fig. 2. Online Supplementary Fig. S4 shows the pcVPC. Overall,
these figures demonstrate that the presented model adequately
describes observed changes in BIS during and after dexmedeto-
midine administration and that all parameters of the model are
estimated with acceptable precision.
We found that changes in plasma dexmedetomidine concen-
trations are reflected in BIS, with a half-life of effect-site equili-
bration of 5.8 min. In unstimulated subjects, half of the maximal
effect (BIS48) is attained at 2.63 ng ml1. In the stimulated state,
patients achieve a BIS value of 48, on average, when the dexme-
detomidine effect-site concentration approaches 7.13 ng ml1.
The post hoc predicted values of C50 and DC50 were found to be
uncorrelated but highly variable within our study population.
Inter-individual variability was estimated to be 69.5 and 81.8%
for C50 and DC50, respectively. The model illustrates that the ef-
fect of stimulation attenuates slowly, with an estimated half-
life of 5.3 min. Moreover, the time for the BIS signal to normalize
is highly variable within our study population, with 95% of the
estimates for the half-life of attenuation between 0.82 and
34.6 min.
Model development for MOAA/S
As a starting point, a linear drug effect model was used to de-
scribe dexmedetomidine-induced changes in the logit of the cu-
mulative probabilities. Subsequently, the model was refined by
introducing the following: (i) an Emax drug effect model
(DAIC¼173.3); and (ii) inter-individual variability on the base-
line logit of observing an MOAA/S score equal to 0 (hLLE0;
DAIC¼187.6). The assumption of proportional odds was chal-
lenged by fitting a differential odds model, as described by
Kjellsson and colleagues.11 The differential odds model had a
slightly lower AIC (DAIC¼6.7) compared with our final model.
However, the condition number of the Fisher information ma-
trix (FIM) was high (1110), and no differences were seen between
the pcVPCs of both models. Based on these findings, we decided
not to implement the differential odds assumption into our final
model.
In line with our approach to model the influence of the rous-
ability on the BIS signal, we evaluated a model with an addi-
tional Emax curve to model potential transient changes in
MOAA/S scores attributable to subject stimulation inherent in
Table 1 Final model parameters with associated relative stan-
dard errors (expressed as percentages) derived from log-likeli-
hood profiling. *Calculated according to:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ex  1p  100%. x,
estimated variance of the inter-individual variability (IIV).
†Derived from log-likelihood profiling. ‡Expressed as SD.
¶Expressed as SD in the logit domain. §Dimensionless parame-
ter. For the volunteer cohort exposed to ambient operating
room noise, the C50 is given by C50 (1DC50,noise cohort)
Final BIS model
Parameter Estimate (RSE%†) IIV* (RSE%†)
h1 Base
§
BIS 96.8 (1.20) 1.34
¶ (56.3)
h2 ke0BIS (min
1) 0.120 (3.80) —
h3 C50 (ng ml
1) 2.63 (15.9) 69.5 (40.2)
h4 DC50
§ 1.71 (18.3) 81.8 (40.8)
h5 kin (min
1) 0.130 (24.6) 122 (41.1)
rRUV,Additive
‡ 10.6 (1.20) —
Final MOAA/S model
Parameter Estimate (RSE%†) IIV* (RSE%†)
h6 hLLE0
§ 10.1 (14.6) 12.5 (37.4)
h7 hD01
§ 0.394 (14.0) —
h8 hD12
§ 1.83 (5.6) —
h9 hD23
§ 1.13 (7.7) —
h10 hD34
§ 1.55 (9.1) —
h11 ke0MOOA/S (min
1) 0.0428 (17.0) —
h12 C50 (ng ml
1) 0.428 (25.6) —
h13 Emax
§ 10.4 (13.3) —
h14 DC50,noise cohort
§ 0.316 (35.0) —
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MOAA/S scoring. This modification led to a marginal improve-
ment in GOF (DAIC¼13.9 for two additional parameters). The
estimate for the half-life of attenuation was significantly lower
than what was found for the BIS model (0.65 vs 5.3 min, respec-
tively), whereas the estimate for the DC50 was significantly
larger (4.21 vs 1.71). The predictive performance, as evaluated by
pcVPC, did not improve, and the model suffered from some nu-
merical difficulties, resulting in a high condition number (1203).
Overall, these findings led us to the decision not to include a
rousability component, describing the time-varying effect of
rousability on the MOAA/S, in our final model.
Covariate screening identified session (background silence
vs background noise session) as a significant covariate.
Inclusion of session as a covariate on the C50 led to a significant
increase in GOF (DAIC¼10.5). The effect of the covariate was
confirmed by graphical analysis of the raw data stratified by
session. This graphical analysis confirmed that the distribution
of MOAA/S scores as a function of TCI targets was different
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Fig 2 Goodness-of-fit plots for the final model. The left panels show the observed BIS vs the post hoc predictions and the CWRES against post hoc predictions and
time. The continuous red line depicts a non-parametric smoother through the data to illustrate lack of bias in the different plots. The right panels show individ-
ual GOF plots for the three subjects with the best, median, and worst fit, respectively. The continuous black line shows the observed MOAA/S scores, whereas
grey circles denote the probability of observing the MOAA/S scores, with bigger circles having higher probabilities. These probabilities were estimated by simula-
tion using the post hoc predicted parameters. Red crosses indicate regions where, according to the simulations, the probability for the observed MOAA/S is<10%.
These points served as ‘residuals’ to instruct on how to refine the model. BIS, bispectral index; CWRES, conditionally weighted residuals; GOF, goodness of fit;
MOAA/S, Modified Observer’s Assessment of Alertness/Sedation.
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between both sessions (data not shown). Inclusion of the covari-
ate did not increase the condition number of the FIM and was
therefore retained in the final model. Age, weight, height, and
sex were found not to have a significant impact on the OFV.
Furthermore, introduction of inter-occasion variability also did
not improve the GOF of the model.
Final model for MOAA/S
The final model parameters and associated standard errors are
shown in Table 1. Online Supplementary Fig. S3 shows the like-
lihood profiles for the final model. The GOF of the final model,
for three subjects representing the best, median, and worst fit,
respectively, is shown in Fig. 2 (post hoc predicted vs observed
MOAA/S scores as a function of time for all subjects are shown
in Online Supplementary Fig. S2). Simulation-based GOF diag-
nostic plots are favoured here owing to the inability to calculate
individually predicted dexmedetomidine plasma concentra-
tions and conditionally weighted residuals-based diagnostic
plots for ordered categorical models. A visual predictive check
for the final model is shown in Online Supplementary Fig. S5.
Overall, these diagnostics show that our final model is ade-
quately developed and that the predictive performance is suffi-
cient to characterize our observations.
The equilibration between effect-site concentrations and
plasma concentrations for dexmedetomidine is fairly slow, with
an estimated half-life for effect-site equilibration of 14 min.
Subjects who were deprived of normal ambient background
noise from the operating room achieved half of the maximal
MOAA/S effect at an effect-site concentration of 0.43 ng ml1.
Volunteers who were exposed to background noises were some-
what more sensitive to the sedative effects of dexmedetomidine
and achieved half of the maximal effect at an effect-site concen-
tration that was, on average, 32% lower (i.e. 0.29 ng ml1).
According to the model, the difference between the logit of
observing an MOAA/S of 0 and an MOAA/S score1 is small
(D01¼0.394). Compared with the other estimates for the differ-
ences in logits, this small estimate results in a fairly low pre-
dicted probability of observing an MOAA/S 1. This is in line with
our observations. Indeed, when we look at the observed propor-
tion of MOAA/S 1 across time (black line in Online
Supplementary Fig. S5) we see that, as opposed to the other
MOAA/S categories, the profile for observing an MOAA/S 1 is rel-
atively flat, not exceeding 10%. An overview of the probability of
observing the different MOAA/S scores as a function of effect-
site concentration is given in Fig. 3 and commented on further
in the Discussion.
Discussion
We developed a PKPD model that characterizes the relationship
between dexmedetomidine plasma concentrations and the re-
sulting changes in BIS and MOAA/S. Owing to the specific char-
acteristics of dexmedetomidine, our models were built taking
into account the time-varying rousability that was introduced
by stimulation of the subject during MOAA/S scoring.
Furthermore, our study protocol was such that we were able to
determine the confounding effect of another type of stimula-
tion, continuous background auditory stimulation, on the seda-
tive properties of dexmedetomidine. A unique characteristic of
our model is that it incorporates the rousability effect on BIS.
Stimulation of subjects at the time of MOAA/S scoring induced a
transient increase in the BIS signal. The effect of the stimulus
diminishes over time and typically disappears within 21 min
(4t1=2) in the absence of stimulation. However, if the subject is
stimulated more frequently, accumulation occurs and the ‘stim-
ulated’ state persists for prolonged periods of time.
Our model also explains the potential for an apparent para-
doxical response of transiently increasing hypnosis (decreasing
BIS) in the presence of decreasing drug concentrations as the in-
dividual transitions from a stimulated to an unstimulated phar-
macodynamic state. This is visible in Fig. 4, where the observed
BIS signals during step-up TCI administration and the subse-
quent recovery for three subjects representing examples of the
best, median, and worst fit of our model against the observed
data are shown. The good agreement between the observed BIS
signal and the post hoc predicted BIS curves (shown in blue) after
single and repeated stimulation inspires confidence in the va-
lidity of our proposed PKPD model.
The basis for our MOAA/S model is an Emax model, using the
logit of cumulative probabilities of MOAA/S scores rather than
the MOAA/S scores themselves. A time-varying rousability ef-
fect similar to the effect found for BIS was not retained in our fi-
nal PKPD model describing MOAA/S observations. When we
tried to estimate the half-life of attenuation, we found an esti-
mate for kin of 1.1 min
1, corresponding to a T1=2 of 0.65 min, indi-
cating that, for the typical patient, the effect of stimulation
disappears within 2.6 min. In the context of our protocol, in
which MOAA/S were scored at least 2 min apart, inclusion of the
time-varying rousability had no significant impact on the pre-
dicted probabilities. However, in other situations, where stimu-
lation occurs more frequently, this might be important, and our
suggested approach could be used to take the confounding ef-
fect of stimulation into account.
Our analysis showed that the C50 for MOAA/S was signifi-
cantly higher, and thus subjects were more responsive, when
deprived of ambient noise in comparison to exposure to ambi-
ent operating room noise. This could be because auditory im-
pulses, such as the name of the volunteer being spoken, are
more clearly perceived against a silent background. However,
our model indicates that even responsiveness towards a painful
stimulus was significantly different between sessions. This
finding was confirmed by graphical analysis (data not shown)
that showed that, after controlling for the TCI target, the fre-
quency of MOAA/S 0 was significantly different between ses-
sions. These results suggest that other more complex
physiological phenomena might govern the interaction between
the presence of background noise and the sedative properties of
dexmedetomidine.
Surprisingly, we found no influence of age on sensitivity to
the sedative effects of dexmedetomidine. Inclusion of age as a
covariate on hLLE0 and C50 in the MOAA/S and BIS model did not
result in a significant decrease in the OFV. In contrast to this
finding, Schnider and colleagues12 and Minto and colleagues13
found that for propofol and remifentanil the sensitivity to EEG
effects increases with age. By including volunteers into our
study in age- and sex-stratified cohorts, we maximized the a pri-
ori possibility of detecting a potential influence of age and sex
on the sedative properties of dexmedetomidine. Nevertheless,
the limited number of subjects in our study could have obscured
an age effect. In contrast, the different receptor pathways in-
volved in dexmedetomidine sedation (a2-receptor agonist) vs
propofol (GABAA receptor agonist) and remifentanil (opioid) se-
dation might explain the lack of an age effect.
Our PKPD models allow us to define target effect-site con-
centrations that maximize the possibility of attaining a particu-
lar level of sedation and inform us on the BIS values that
correspond to these sedation levels. In a subject exposed to
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ambient operating room noise, loss of responsiveness to verbal
stimulation (i.e. MOAA/S score2) is predicted to occur at
an effect-site concentration of 0.91 ng ml1. At this effect-
site concentration, BIS immediately before the MOAA/S stimula-
tion is 72. Volunteers deprived of ambient noise lose respon-
siveness to verbal stimulation at a Ce of 1.3 ng ml
1 and BIS
value of 64.
Based on a study in healthy volunteers, Kasuya and
colleagues14 found that the correlation between BIS and MOAA/
S scales is significantly different between dexmedetomidine
and propofol. When considering the same level of sedation, BIS
values for dexmedetomidine were generally lower than those in
the propofol group. Our analysis contradicts these findings. The
results in Table 2 are in (very) good agreement with earlier work
on propofol. Struys and colleagues15 found that for propofol the
BIS values where 50% of the population loses responsiveness
(BIS50) to MOAA/S scales 5, 4, and 3 were 85, 74, and 66, respec-
tively. However, earlier findings by Kearse and colleagues16 and
Iselin-Chaves and colleagues17 showed that the BIS50 for loss of
responsiveness to verbal stimulation was 65 and 64, respec-
tively. These results are in good agreement with our estimates
for dexmedetomidine, indicating that the calibration for BIS is
very similar between dexmedetomidine and propofol. Overall,
these findings suggest that target BIS values between 60 and 40,
which generally indicate adequate general anaesthesia, are ap-
propriate when dexmedetomidine-based deep sedation is re-
quired. Between these target BIS values, corresponding to a Ce of
1.6 and 3.6 ng ml1, loss of responsiveness to verbal stimulation
is predicted to occur in 58 and 81% of patients, respectively, and
MOAA/S scores will be2.
Besides the discrepancy with the work of Kasuya and
colleagues,14 our results are generally in line with earlier reports
from experimental studies with dexmedetomidine in healthy
volunteers. In a study where healthy volunteers received dex-
medetomidine in a step-up TCI titration, Kaskinoro and




































0.01 0.1 1 10







Fig 3 Relationship between effect-site concentrations and BIS and MOAA/S. The continuous black line is the predicted BIS, whereas the MOAA/S with the highest
probability is shown with a continuous red line. Stacked bar plots illustrate the distribution of MOAA/S probabilities at effect-site concentrations of 0.01, 1.0, 2.5,
and 10 ng ml1, corresponding to predicted BIS values of 96, 70, 50, and 20, respectively. Ce, effect-site concentration; BIS, bispectral index; MOAA/S, Modified
Observer’s Assessment of Alertness/Sedation.
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verbal stimulation occurred at 1.9 ng ml1. Although it is not en-
tirely clear whether volunteers were exposed to or deprived of
ambient noise, this concentration is in agreement with our pre-
dictions, considering the variability associated with assessment
of loss of responsiveness to verbal stimulation. In a study where
healthy volunteers received a 10 min 6 mg kg1 h1 loading dose
followed by a 0.2 or 0.6 mg kg1 h1 i.v. infusion, Hall and
colleagues19 found that BIS decreased by 31 and 36% after
60 min. When we simulated a similar experimental study, we
found a 21 and 28% decrease in BIS, which is slightly lower, but
still inspires confidence given that we are dealing with an inde-
pendent data set and that it is not clear whether volunteers in
the study by Hall and colleagues19 were stimulated, which could
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Fig 4 Observed (pink lines) and post hoc predicted BIS (blue lines) for the subjects with the best, median, and worst fit. The dashed vertical lines indicate when a
new TCI target was set. Immediately before this, MOAA/S was assessed. BIS, bispectral index; MOAA/S, Modified Observer’s Assessment of Alertness/Sedation;
TCI, target-controlled infusion.
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The approach we present, which models the drug effect in
both the unstimulated and the stimulated state, was used previ-
ously by Heyse and colleagues20 to account for the differences
in hypnotic and analgesic effects between stimulated and unsti-
mulated volunteers receiving sevoflurane–remifentanil anaes-
thesia. However, in contrast to the analysis of Heyse and
colleagues,20 we used this approach to account for the time-
varying effect of stimulation. Correcting for the confounding ef-
fect of stimulation is pivotal for modelling dexmedetomidine.
Not only does it significantly increase the GOF, without the
rousability component in the model a significant bias is seen in
estimated PKPD parameters. For example, the C50 for BIS, which
is the parameter of primary interest, increases by 82% after
stimulation. Dosing regimens taking into account both the pre-
and post-stimulation effects with dexmedetomidine could
result in better titration, targeting values with the highest prob-
ability for the desired MOAA/S. If deep sedation is required, the
target that results in the least increase in BIS without oversedat-
ing the patient could be chosen. Whenever BIS is used to target
a specific degree of sedation with dexmedetomidine, one should
be aware of the confounding effect of stimulation. An applied
stimulus is expected to disturb the BIS signal for up to 20 min.
Implementing our model into a drug display could correct for
this time-varying effect of stimulation and could provide a more
robust system to titrate dexmedetomidine-based sedation.
In conclusion, we present a PKPD model that adequately de-
scribes the sedative and hypnotic effects of dexmedetomidine
in healthy volunteers. This model integrates the well-known
rousability associated with dexmedetomidine sedation and ac-
counts for changes in responsiveness between volunteers at-
tributable to repeated auditory stimulation. After validation of
our PKPD model in a patient population, our model might be
used to transition towards effect-site TCI rather than plasma
concentration TCI for dexmedetomidine in clinical practice,
thereby allowing tighter control over the desired level of
sedation.
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